Revance Therapeutics, Inc. (RVNC)

Feb 6, 2025 = RVNC was delisted (reason: acquired by Crown Laboratories)

3.650

0.00 (0.00%)

Inactive · Last trade price on Feb 6, 2025

Revance Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	256.95	234.04	132.57	77.8	15.33	0.41
Revenue Growth	25.82%	76.55%	70.40%	407.65%	3610.65%	-88.92%
Gross Profit	103.69	81.88	-20.39	-61.87	-115.24	-102.45
Operating Income	-193.71	-220.73	-272.17	-274.68	-269.26	-164.46
Net Income	-184.44	-323.99	-356.42	-281.31	-282.09	-159.43
Earnings Per Share	-1.91	-3.83	-4.90	-4.17	-4.86	-3.67
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Cash & Investments	184.08	253.92	340.71	225.07	436.51	290.12
Total Debt	483.45	478.43	418.47	324.51	212.11	29.34
Net Cash (Debt)	-299.37	-224.52	-77.76	-99.44	224.4	260.78
Net Cash Growth	-	-	-	-	-13.95%	48.33%
Net Cash Per Share	-3.09	-2.65	-1.07	-1.47	3.87	6.00

Cash Flow & CapEx

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Operating Cash Flow	-190.89	-216.58	-193.55	-221.54	-178.5	-106.16
Capital Expenditures	-4.02	-6.89	-3.21	-10.38	-4.1	-3.23
Free Cash Flow	-194.91	-223.46	-196.76	-231.91	-182.6	-109.39
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Gross Margin	40.35%	34.98%	-15.38%	-79.52%	-	-
Operating Margin	-75.39%	-94.31%	-205.31%	-353.06%	-1757.01%	-39820.58%
Pretax Margin	-117.35%	-138.30%	-268.34%	-361.59%	-1857.81%	-38602.66%
Profit Margin	-71.78%	-138.43%	-268.87%	-361.59%	-1840.71%	-38602.66%
FCF Margin	-75.86%	-95.48%	-148.42%	-298.10%	-1191.52%	-26486.93%

Valuation

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Aug '26 Aug 18, 2026	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
PS Ratio	-	3.30	11.46	15.06	123.07	1988.80